Cargando…

The Efficacy and Safety of Pulmonary Vasodilators in Pediatric Pulmonary Hypertension (PH): A Systematic Review and Meta-analysis

Background: We performed a meta-analysis to evaluate the efficacy and safety of pulmonary vasodilators in pediatric pulmonary hypertension (PH) patients. Methods: We searched electronic databases including PubMed, EMBASE, and the Cochrane Library up to May 2020, and conducted a subgroup analysis for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shu, Tingting, Chen, Huaqiao, Wang, Lu, Wang, Wuwan, Feng, Panpan, Xiang, Rui, Wen, Li, Huang, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103162/ https://www.ncbi.nlm.nih.gov/pubmed/33967811 http://dx.doi.org/10.3389/fphar.2021.668902

Ejemplares similares

The efficacy and safety of pulmonary vasodilators in patients with Fontan circulation: a meta-analysis of randomized controlled trials
por: Wang, Wuwan, et al.
Publicado: (2019)

Association of statin use and the risk of recurrent pulmonary embolism in real-world Chinese population
por: Wang, Lu, et al.
Publicado: (2021)

Efficacy and safety of pulmonary vasodilators in the patients with Eisenmenger syndrome: a meta-analysis of randomized controlled trials
por: Hou, Yulin, et al.
Publicado: (2021)

Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis
por: Liu, Yu-Yang, et al.
Publicado: (2023)

Efficacy and safety of oral pulmonary vasodilators in pulmonary veno‐occlusive disease
por: Nakamura, Junichi, et al.
Publicado: (2022)

Corrigendum: Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis
por: Liu, Yu-Yang, et al.
Publicado: (2023)

Efficacy evaluation of pulmonary hypertension therapy in patients with portal pulmonary hypertension: A systematic review and meta-analysis
por: Zhang, Ruihua, et al.
Publicado: (2022)

Clinical Efficacy and Safety of Different Doses of Sildenafil in the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Network Meta-analysis
por: Sun, Linli, et al.
Publicado: (2021)

Effectiveness of pulmonary vasodilators on pulmonary hypertension associated with POEMS syndrome
por: Ohashi, Kana, et al.
Publicado: (2019)

Children with Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension Treated with Pulmonary Vasodilators—The Pediatric Cardiologist Point of View
por: Migdał, Anna, et al.
Publicado: (2021)

Oxygen-Sensitivity and Pulmonary Selectivity of Vasodilators as Potential Drugs for Pulmonary Hypertension
por: Morales-Cano, Daniel, et al.
Publicado: (2021)

Balloon pulmonary angioplasty vs riociguat in patients with inoperable chronic thromboembolic pulmonary hypertension: A systematic review and meta‐analysis
por: Wang, Wuwan, et al.
Publicado: (2019)

Inhaled pulmonary vasodilators for persistent pulmonary hypertension of the newborn: safety issues relating to drug administration and delivery devices
por: Cosa, Nathan, et al.
Publicado: (2016)

Effects of Different Pulmonary Vasodilators on Arterial Saturation in a Model of Pulmonary Hypertension
por: Becker, Eva Maria, et al.
Publicado: (2013)

Pulmonary vasodilators: beyond the bounds of pulmonary arterial hypertension therapy in COVID-19
por: Franco, Veronica, et al.
Publicado: (2020)

Improvement of pulmonary arterial compliance by pulmonary vasodilator in pulmonary hypertension from combined pulmonary fibrosis and emphysema
por: Kusaka, Kei, et al.
Publicado: (2019)

Comparison of Balloon Pulmonary Angioplasty and Pulmonary Vasodilators for Inoperable Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review and Meta-Analysis
por: Kalra, Rajat, et al.
Publicado: (2020)

Role of heparanase in pulmonary hypertension
por: Wang, Lin-Jun, et al.
Publicado: (2023)

Management of pulmonary vasodilator therapy in patients with pulmonary arterial hypertension during critical illness
por: Muzevich, Katie M, et al.
Publicado: (2014)

Statins for the Treatment of Pulmonary Hypertension in Patients with Chronic Obstructive Pulmonary Disease
por: Chen, Chung-Yu, et al.
Publicado: (2021)

The Efficacy and Safety of Revefenacin for the Treatment of Chronic Obstructive Pulmonary Disease: A Systematic Review
por: Zhang, Jiaxing, et al.
Publicado: (2021)

Efficacy of immunosuppressants with bridge vasodilator therapy in severe lupus erythematosus‐associated pulmonary arterial hypertension
por: Sanges, Sébastien, et al.
Publicado: (2019)

Maprotiline Prevents Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats
por: Tong, Yi, et al.
Publicado: (2018)

Upregulation of IRF9 Contributes to Pulmonary Artery Smooth Muscle Cell Proliferation During Pulmonary Arterial Hypertension
por: Chen, Yong-Jie, et al.
Publicado: (2021)

Adenosine as pulmonary vasodilator in ARDS
por: Molina, JM, et al.
Publicado: (1998)

Combined Methods (Formal Adjusted Indirect Comparison, Meta-Analysis and Principal Component Analysis) Comparisons of the Safety and Efficacy of Ambrisentan, Bosentan, and Sildenafil in the Patients With Pulmonary Arterial Hypertension
por: Li, Xinmei, et al.
Publicado: (2020)

Therapeutic Strategies in Pulmonary Hypertension
por: Fuso, Leonello, et al.
Publicado: (2011)

Additional Use of Prostacyclin Analogs in Patients With Pulmonary Arterial Hypertension: A Meta-Analysis
por: Wang, Pengwei, et al.
Publicado: (2022)

Dramatic and sustained responsiveness of pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension to vasodilator therapy
por: May, Adam, et al.
Publicado: (2014)

Acute vasodilator testing: An opportunity to advance the precision care of pulmonary hypertension
por: Cirulis, Meghan M., et al.
Publicado: (2019)

Review of Natural Resources With Vasodilation: Traditional Medicinal Plants, Natural Products, and Their Mechanism and Clinical Efficacy
por: Tang, Fei, et al.
Publicado: (2021)

Analysis of the safety and efficacy of different plasma concentrations of pirfenidone in patients with idiopathic pulmonary fibrosis
por: Li, Hui, et al.
Publicado: (2022)

Laryngopharyngeal pH Monitoring in Patients With Idiopathic Pulmonary Fibrosis
por: Su, Yiliang, et al.
Publicado: (2021)

Insulin Resistance and Pellino-1 Mediated Decrease in the Activities of Vasodilator Signaling Contributes to Sunitinib-Induced Hypertension
por: Liu, Yang, et al.
Publicado: (2021)

Multidisciplinary Team Managements and Clinical Outcomes in Patients With Pulmonary Arterial Hypertension During the Perinatal Period
por: Shu, Tingting, et al.
Publicado: (2021)

Pulmonary vasodilators can lead to various complications in pulmonary “arterial” hypertension associated with congenital heart disease
por: Chida-Nagai, Ayako, et al.
Publicado: (2020)

Outcomes of pulmonary vasodilator use in Veterans with pulmonary hypertension associated with left heart disease and lung disease
por: Gillmeyer, Kari R., et al.
Publicado: (2021)

Beneficial Effects of Pulmonary Vasodilators on Pre-Capillary Pulmonary Hypertension in Patients with Chronic Kidney Disease on Hemodialysis
por: Kimuro, Keiji, et al.
Publicado: (2022)

Pulmonary vasodilator therapy in sarcoidosis‐associated pulmonary hypertension may decrease lung function decline and mortality
por: Gayen, Shameek, et al.
Publicado: (2023)

Inhaled pulmonary vasodilators in refractory hypoxemia
por: Wright, Brian J.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_34md2knf03ukaadp0pt5de2tgh